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Abstract: Syndromic retinitis pigmentosa (RP) is the result of several mutations expressed in rod photoreceptors, over 40 
of which have so far been identified. Enormous efforts are being made to relate the advances in unraveling the patho-
physiological mechanisms to therapeutic approaches in animal models, and eventually in clinical trials on humans. This 
review summarizes briefly the current clinical management of RP and focuses on the new exciting treatment possibilities. 
To date, there is no approved therapy able to stop the evolution of RP or restore vision. The current management includes 
an attempt at slowing down the degenerative process by vitamin supplementation, trying to treat ocular complications and 
to provide psychological support to blind patients. Novel therapeutic may be tailored dependant on the stage of the disease 
and can be divided in three groups. In the early stages, when there are surviving photoreceptors, the first approach would 
be to try to halt the degeneration by correction of the underlying biochemical abnormality in the visual cycle using gene 
therapy or pharmacological treatment. A second approach aims to cope with photoreceptor cell death using neurotrophic 
growth factors or anti-apoptotic factors, reducing the production of retino-toxic molecules, and limiting oxidative damage. 
In advanced stages, when there are few or no functional photoreceptors, strategies that may benefit include retinal 
transplantation, electronic retinal implants or a newly described optogenetic technique using a light-activated channel to 
genetically resensitize remnant cone-photoreceptor cells. 
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INTRODUCTION 
  The term retinitis pigmentosa (RP) encompasses a 
heterogeneous group of disorders that result in an initial loss 
of rod photoreceptors, followed by a detrimental effect on 
cone photoreceptors, inner nuclear layers, ganglion cells and 
retinal pigment epithelium (RPE) [1, 2]. 
  Rods represent 95% of all the photoreceptors in the 
humans [3] and are responsible for scotopic vision, while 
cones are responsible for photopic vision, color vision and 
fine vision and increase in density towards the centre of the 
macula [4]. 
  The photoreceptors consist of an outer segment (OS), an 
inner segment, a cell body and a synaptic terminal where 
neurotransmission occurs to second order neurons. The OS 
discs are renewed in a circadian rhythm from the base of the 
photoreceptor OS, the RPE engulfs the distal discs where 
they undergo degradation by phagocytosis, thus keeping the 
length of the OS constant [5]. Each OS contains several 
million visual pigment molecules called opsin and vitamin A  
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chromophore, retinal [6]. Photo-activation results in the 
isomerisation of 11 cis-retinal to all-trans-retinal. Continued 
function of the photoreceptors requires the removal of the 
all-trans-retinal and resupply of the chromophore by the RPE 
cells [7]. All-trans retinyl esters are the substrate for RPE 
protein 65 (RPE65). In the rod OS, the transmembrane 
proteins peripherin/retinal degeneration slow (RDS) [8], 
retinal outer segment protein 1 (ROM1) [9], and rim protein 
ABCA4 [10] have been studied in the context of RP. 
ABCA4 encodes the rod and cone photoreceptor rim protein, 
which is a member of the adenosine triphosphate (ATP)-
binding cassette transporter family [11]. It plays a major role 
in clearance of all-trans-retinal from the disk membranes 
after photo-excitation of rhodopsin. The most probable 
substrate of ABCA4 is N-retinylidene- PE, a product of the 
reaction of all-trans-retinal with phosphatidylethanolamine. 
During the process of disk shedding, these compounds, of 
which the best studied is A2E, accumulate in the cells of 
RPE, which ultimately leads to RPE cell death and 
concomitant degeneration of photoreceptors [12]. 
  Non-syndromic RP is the result of several mutations 
expressed in rod photoreceptors, 44 of which have been 
identified so far [13] (See http://www.sph.uth.tmc.edu/retnet/ 
sum-dis.htm for updated genes and loci). These include 
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cascade, structural protein mutations in peripherin/RDS or 
ABCA4, genes expressed in RPE and coding proteins 
involved in vitamin A metabolism such as RPE65. These 
mutations may affect the renewal and shedding of the 
photoreceptor OS, the visual transduction cycle and/or the 
vitamin A (retinol) metabolism [4]. The retinal phenotypes 
associated with ABCA4 depend on the severity of the 
mutation and the remaining activity of the rim protein; 
patients with two severe alleles and no rim protein activity 
may have RP [10]. 
  Enormous efforts are being made to relate the advances 
in unraveling the patho-physiological mechanisms to 
therapeutic approaches in animal models, and eventually in 
clinical trials. This review summarizes briefly the current 
clinical management of RP and focuses on the new exciting 
treatment possibilities. 
CURRENT CLINICAL MANAGEMENT 
  To date, there is no approved therapy able to stop the 
evolution of RP or restore vision, so the current management 
aims to slow down the degenerative process, to treat ocular 
complications and to provide psychological support to blind 
patients [14]. 
  Vitamin therapy has been suggested for almost twenty 
years as a possible way to slow down the retinal 
degenerating process [15]. Berson et al. extensively 
investigated the trophic and anti-oxidants effects of vitamins 
A and E, respectively, on photoreceptors. Long-term vitamin 
A supplementation at doses of 15,000 units/day has been 
suggested to reduce the loss of ERG amplitude, while 
vitamin E supplementation at 400 units/day was thought to 
have adverse effects [16]. Further studies from the same 
group have shown that supplementation with 1200 mg/day of 
docosahexaenoic acid (DHA) in addition to vitamin A 
initially slowed down the course of the disease, but this 
beneficial effect did not last over two years [17]. The most 
recent study from this group supports the use of 12 mg/day 
of lutein to slow visual field loss among nonsmoking adults 
with RP taking vitamin A supplementation [18]. The 
suggested dietary protocol includes the daily intake of 
15,000 units of vitamin A, 12 mg of lutein and 1 to 2 three-
oz servings of oily fish per week. However, as wittily argued 
by Massof and Fishman in the editorial introducing Berson’s 
work on lutein supplementation, none
  of the studies on 
vitamin supplementation convincingly proved to be effective 
in slowing the rate of progression of RP as the investigators 
made strong arguments based on secondary analyses of 
subgroup data and, therefore, do not warrant mandating a 
change in how patients
 with RP are treated [19]. 
  Moreover, Vitamin A could be toxic and should be 
avoided in patients with mutations in ABCA4 gene and 
women planning to conceive or with severe osteoporosis. 
Liver enzymes, levels of serum retinol and triglyceride 
should be regularly checked in all patients taking such 
supplementation. 
  The most common ocular complications of RP are: 
posterior central sub-capsular cataract, which can be 
successfully treated with phacoemulsification and 
implantation of intraocular lens [20]; macular edema, which 
can be treated with oral carbonic anhydrase inhibitors 
(acetazolamide sodium 250 mg BID) [21] or sustained 
topical dorzolamide therapy [22], with inconstant results; 
mild inflammatory reactions, which do not require treatment. 
  It seems to be appropriate, especially in the early stages 
of the disease, to suggest that RP patients protect their 
retinas from excessive light. Experiments on photic damage 
to the retinas of rats with hereditary retinal dystrophy and 
some tentative clinical evidence on human patients suggest 
that, in human RP, one could try to protect the rods from 
bright light in an attempt to delay the retinal degeneration 
and to prolong the period of useful vision [23]. Hence the 
use of low vision aids, especially the use of tinted lenses that 
filter short wavelength Light, can be of benefit in controlling 
glare and protecting the retina from photopic damage [24]. 
  In later stages of the disease, low vision aids may also be 
beneficial in maximizing the limited vision. Professional 
psychological help as well as supportive patients’ 
associations are also fundamental when dealing with RP 
patients at the final, blinding, stage of disease. At the time of 
diagnosis, patients should be informed of the visual 
prognosis and orientated towards institutions that help them 
to rehabilitate and obtain new skills. If left to themselves, RP 
patients have been reported to have difficulties in adjusting 
to their visual loss particularly with respect to health-care 
orientation, vocational environment, social environment, and 
extended family relationships [25]. 
FUTURE TREATMENTS 
  Multiple factors, genomic, biochemical and cellular 
responses, reduce the viability of photoreceptors in inherited 
retinal dystrophies. Novel therapeutic approaches have been 
tailored dependant on the stage of the disease and can be 
divided in three groups [26]. In the early stages, when there 
are surviving photoreceptors, the first approach is to try to 
halt the degeneration by correction of the underlying 
biochemical abnormality in the visual cycle using gene 
therapy or pharmacological treatment. A second approach 
aims to cope with photoreceptor cell death using 
neurotrophic growth factors or anti-apoptotic factors, 
reducing the production of retino-toxic molecules, and 
limiting oxidative damage. In advanced stages, when there 
are few or no functional photoreceptors, strategies that may 
benefit include retinal transplantation, electronic retinal 
implants or a newly described optogenetic technique using a 
light-activated channel to genetically resensitize remnant 
cone-photoreceptor cells. 
GENE THERAPY 
  Gene therapy works best for diseases resulting from the 
reduction or absence of a protein with an essential function. 
Assuming a lack of secondary changes, targeting the gene 
encoding this protein could result in a therapeutic benefit. 
The principle of gene therapy is the transfer of a therapeutic 
gene by use of viral or non-viral vectors and requires genetic 
modification of the ocular cells to produce its therapeutic 
effect. Gene therapy strategies however differ depending on 
if the exact gene and type of mutation is known, thus the 
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  Methods suggested to replace or correct abnormal genes 
can classified into two groups: (1) gene augmentation 
therapies, where a normal gene is inserted into the genome to 
replace nonviable or diseased genes using a carrier vector, 
(2) gene silencing therapies, in which the expression of the 
mutated gene is inhibited by use of ribozyme or RNA 
interference.  
Gene Augmentation 
  In autosomal recessive and X-linked RP, mutations 
usually lead to a loss of function and the principle of gene 
therapy is to introduce a wild-type version of the mutated 
gene into the cells in which normal functioning of this gene 
is required [27]. Successful gene therapy is dependent on 
efficient transduction of the target cell and sustained 
expression of the recombinant virus at a sufficient level. 
Adeno-associated virus (AAV), a nonpathogenic parvovirus, 
has been the most successful vector owing to its ability to 
transduce a variety of non-dividing cell types [28, 29]. RPE 
cells take up and express recombinant viruses at high 
efficiency, which represents an important advantage of this 
approach. Moreover, the immune-privileged status of the eye 
prevents problems with undesirable immune response to 
AAV.  
  This therapy has been most extensively studied in 
Leber’s congenital amaurosis (LCA) with mutation in 
RPE65, which interrupts function of the visual cycle [30]. 
Preliminary trials involving surgical delivery of recombinant 
AAV carrying wild type rpe65 into the subretinal space of 
the Briard dog, a natural occurring model with mutation in 
the RPE65 gene, demonstrated dramatic improvements in the 
light sensitivity of rods and cones [31-35]. Importantly, 
expression of Rpe65 and restoration of vision in the treated 
dogs was stable over the four-year study period [36]. More 
than 50 dogs have been treated using this approach, with 
95% showing restored vision [37]. The availability of animal 
models of this condition has enabled preclinical studies of 
safety and efficacy [38]. Three human clinical trials using 
AAV serotype 2 reported their findings separately in 9 
patients in 2008 [39-41]. To date, over 30 patients have so 
far received the gene therapy, ranging in follow up from 90 
days to 1.5 years. No major side effects have been reported 
[42,43]. Most patients have shown a sustained improvement 
in subjective and objective measurements of vision (i.e., dark 
adaptometry, pupillometry, electroretinography, nystagmus, 
and ambulatory behavior). The greatest improvement was 
noted in children, all of who gained ambulatory vision, 
suggesting that early intervention would result in the best 
potential gain [44]. 
Combined Gene-Silencing and Gene Replacement 
  Autosomal dominant conditions are mainly caused by 
toxic gain of function mutations that result in either a 
mutated protein or a negative effect of the encoded protein. 
Mutations within the rhodopsin gene account for 
approximately 25% of the cases of autosomal dominant RP, 
the rest are not linked to rhodopsin. In RP the aberrant gene 
product is detrimental to the photoreceptors and ultimately 
results in cell death. Two approaches have been proposed to 
silence the abnormal gene: ribozymes and RNA interference 
(siRNA). 
  Ribozymes can be designed to cleave mutant mRNA 
molecules so that the mutant rhodopsin is not produced [45]. 
The use of ribozyme therapy is however limited by being 
mutation dependent. This would mean, in the case of 
rhodopsin alone, targeting more than 100 different alleles. 
  siRNA, on the other hand, is a mutation independent 
technique for posttranslational gene silencing [46]. Complete 
down-regulation of endogenous rhodopsin can be achieved 
using this method. The second part of this therapy involves 
the introduction of a codon modified rhodopsin cDNA that is 
not sensitive to the siRNA interference via AAV serotype 5 
vector mediated gene transfer [47, 48]. The safety of this 
technique has yet to be established in large animal and 
human experiments. 
PHARMACOLOGICAL TREATMENT 
  Pharmacological agents can also compensate for a 
biochemical defect and can be a good choice in those cases 
where some aspects of the patho-physiological mechanism 
are known. The main advantage of such treatment is that the 
eventual toxicity of the drug is known and can be modulated. 
This strategy may be applicable to RP with a primary deficit 
in chromophore biosynthesis causing an alteration of the 
visual cycle. Examples include LCA owing to mutations in 
the LRAT and RPE65 genes. 
  The first experiments aimed at bypassing the biochemical 
defect caused by the absence of RPE65 were performed by 
oral administration of 9-cis-retinyl acetate in RPE65-
deficient mice [49, 50]. Electroretinogram (ERG) recordings 
documented restored light sensitivity, increasing with the 
number of doses and sustained up to six months after 
treatment. Similar recovery of visual function was observed 
following intra-peritoneal injection of 11-cis-RAL into 
RPE65-deficient mice [51]. 
  High doses of retinoids have been shown to be toxic in 
numerous studies, including teratogenic effects. However, 
acute and prolonged treatment of mice with 9-cis-retinoids 
did not cause obvious adverse effects, raising the hope for a 
trial of chromophore supplementation in humans [30]. 
NEUROPROTECTION 
  RP is a genetically heterogeneous disease where only 
60% of the mutations are known [52]. Genetic strategies are 
dependent on the identification of the gene mutation, and are 
therefore restricted in their application. Neuroprotection is a 
therapeutic strategy for the treatment of retinal 
neurodegenerative disease that is independent of the etiology 
of the degeneration. The aim is to provide a protective 
environment to prolong the viability of the photoreceptors by 
their effect on the secondary biochemical pathways. This can 
be achieved either by delivering neurotrophic growth factors, 
or inhibiting pro-apoptotic pathways, or implementing 
viability factors such as the rod-derived cone viability factor 
(RdCVF). 
Neurotrophic Factors 
  There have been a number of examples of neurotrophic 
factors being successfully tested in animal models for 
neurodegenerative diseases, but failing to bring any benefit 
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glial cell-derived neurotrophic factor (GDNF) for Parkinson 
disease [53] or ciliary neurotrophic factor (CNTF) for 
amyotrophic lateral sclerosis [54]. These experiences show 
that the efficacy of neurotrophic factors in treating human 
disease remains to be established, and the delivery of these 
factors is problematic as they have a short half-life [55]. 
  A number of agents that slow photoreceptor death in 
animal models have been identified: basic fibroblast-derived 
growth factor (bFGF), brain-derived neurotrophic factor 
(BDNF), cardiotrophin-1, nerve growth factor (NGF), 
fibroblast growth factor (FGF) and CNTF. 
 Faktorovich  et al. demonstrated the neuroprotective 
effect of bFGF in 1990 [56]. Since iterative intravitreal 
injections are not recommended, other strategies have been 
tried, such as the use of encapsulated cells producing bFGF 
placed in the vitreous cavity [57]. However, the occurrence 
of major side effects such as retinal revascularization has 
excluded its utility in a clinical setting. 
  The use of encapsulated cells secreting CNTF into the 
vitreous has been extensively studied and has shown 
preservation of retinal integrity in different animal models 
[58]. A phase I safety trial on 10 participants over a period of 
six months using an intravitreal implant device (NT-501, 
Neurotech USA) was well tolerated [59]. A positive trend in 
visual acuity was also noted, however ERG responses were 
inconsistent. A phase III clinical trial is currently ongoing to 
investigate whether CNTF can improve photoreceptor 
function, in terms of visual acuity and visual field sensitivity, 
in RP patients [60]. 
Inhibitors of Apoptosis  
  A final common pathway of all types of RP is 
photoreceptor cell death [61]. Leonard et al. reported their 
non-specific approach targeting the apoptotic pathway 
involving a family of cysteine proteases known as caspases 
[62]. The X-linked inhibitor of apoptosis (XIAP) protein is 
thought to be the most potent member and this group 
employed AAV mediated delivery of XIAP to study its 
neuroprotective effect. XIAP treated eyes of homozygous 
albino transgenic rats had significantly preserved outer 
nuclear layer than their contra-lateral untreated counterparts. 
The authors believe that this technique may be more widely 
applicable as it is independent of mutation. 
Calpain Inhibitors 
  Recent evidence derived from studies on retinal 
degeneration (rd1) human homologous mouse model for RP 
suggests that photoreceptor cell death may result primarily 
from non-apoptotic mechanisms, where photoreceptor cell 
death appears to be governed by, among other things, 
changes in cyclic nucleotide metabolism, down-regulation of 
the transcription factor CREB, and excessive activation of 
calpain and PARP [63]. Pharmacological inhibition of 
calpain activity in rd1 organotypic retinal explants using the 
highly specific calpain inhibitor calpastatin peptide reduced 
photoreceptor cell death in vitro after both short and 
prolonged exposure, an effect that was also evident after in 
vivo application via  intravitreal injection. These findings 
highlight the importance of calpain activation for 
photoreceptor cell death but also for photoreceptor survival 
and propose the use of highly specific calpain inhibitors to 
prevent or delay RP [64]. 
Rod-Derived Cone Viability Factor 
  Cone death in RP is also caused by lack of surviving 
factors released by the normal retina. This has been 
confirmed by the discovery that rods generate a diffusible 
factors stimulating cone survival in the retinal degeneration 
mouse model [65]. One of the trophic factors has been 
identified by expression cloning and named rod-derived cone 
viability factor (RdCVF) [66]. RdCVF protein injections in a 
frequent type of rhodopsin mutation, the P23H rat, induced 
an increase in cone cell number and, more important, a 
further increase in the corresponding ERG, making it a 
promising therapeutic option [67]. 
ELECTRONIC RETINAL IMPLANTS 
  Gene therapy and neuroprotective agents play a role in 
rescuing and preventing the loss of photoreceptors. 
However, in advanced stages of the disease, where the loss 
of photoreceptors is already established, and for the majority 
of patients in which the mutation is not known, the electronic 
implants or artificial retina can be an option for restoration of 
vision. 
  One of the best examples of electronic devices used in 
medicine are the cochlear implants to treat deafness [68]. In 
the eye, the electronic devices are meant to replace dead or 
degenerated photoreceptor cells. These devices capture 
images and convert them into an electronic signal. The 
electronic signal is sent to the retinal secondary neurons 
(ganglion cells, bipolar cells, etc.) that transmit it to the 
visual cortex via the optic nerve and pathway. Hence, these 
devices must be able to connect with viable secondary 
neurons. Several studies have demonstrated the viability of 
these secondary neurons in patients with RP [69]. Optical 
coherence tomography (OCT) has been used as a objective 
non-invasive method to assess the presence of viable inner 
retinal neurons (secondary neurons) [70] and study the 
tolerability and long-term effects on the retina of electronic 
prosthesis. 
  There are four main types of electronic implants 
developed so far: cortical visual prosthesis, supra-choroidal 
implant, epiretinal implant and subretinal implants. 
Cortical Visual Prosthesis 
  It is based on direct stimulation of the visual cortex 
bypassing the eye. A group from the Illinois Institute of 
Technology is planning the first human intra-cortical visual 
prosthesis [71]. 
Supra-Choroidal Implant 
 Tokuda  et al. have implanted on rabbit retina a multi-
chip flexible stimulator in the supra-choroidal sclera, 
successfully obtaining Electrically Evoked Potential on 
visual cortex evoked by the multi-chip stimulator [72]. 
Epiretinal Implant 
  The implant is tacked to the surface of the inner retina. 
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Learning Retina Implant developed by Feucht et al. [73], the 
EPI-RET project that uses an intraocular lens (IOL)-type 
receiver unit [74], and the group at the Doheny Eye Institute, 
USC Medical School, in conjunction with Second Sight 
Medical Products (SSMP). The latter, known as the Argus II 
retinal prosthesis system, consists of a surgically implanted 
60-electrode stimulating microelectrode array. Recently, in a 
study on the largest cohort of visual prosthesis recipients to 
date (27 patients), they found that artificial vision augments 
information from existing vision in a spatial-motor task [75]. 
Subretinal Implant 
  The implant is placed subretinal above the RPE. 
Theoretically, this is the most physiological placement, as it 
is placed were the damaged photoreceptors are located. 
Zrenner et al. from the University of Tubingen, Germany, 
have implanted a subretinal prosthesis in humans and have 
detected restoration of photoreceptor function via electronic 
devices electrically coupled to inner retinal neurons [76]. 
The implant, placed under the macular region, contains an 
array of 1500 active micro-photodiodes (‘chip’). Three 
previously blind patients with RP could locate bright objects 
on a dark table; two of them differentiated correctly the 
direction of fine stripe-patterns. One patient also 
spontaneously reported new objects with typical shapes such 
as a banana. He was able to discern shades of grey with only 
15% contrast, to localize and approach a person freely, to 
read the hands of a clock face, and to read letters of the 
alphabet at room light and combine them to words, even to 
the point of spontaneously identifying a deliberate spelling 
mistake. 
  Another project based on the subretinal implant is the 
Boston Retinal Implant Project developed by Rizzo et al. 
[77]. They have assessed the concordance of the form of 
induced perception and the pattern of electrical stimulation 
of the retina, and the reproducibility of the responses in five 
patients affected with severe RP. 
  Several clinical studies have demonstrated the tolerance 
of the implanted devices, with the exception of the EPI-RET 
with a large IOL-type receiver unit that caused retinal 
disruption in a rabbit model [74]. However, the visual 
benefit is not straight forward, as even limited sight 
restoration is a slow, learning process that takes months for 
improvement to become evident [78]. The learning curve 
could be expected to be easier in younger patients and earlier 
stages of the disease, due to neuronal plasticity. 
  In order to properly assess the performance of these 
artificial retinas there is a need for development of 
standardized visual tests. These should be able to detect 
small improvements in vision in patients with advanced RP 
and capture aspects that relate to a better quality of life [78]. 
  Devices with new, sophisticated designs and increasing 
numbers of electrodes as well the possibility of using 
adjunctive therapy, such as neurotrophic agents [79], could 
allow for long-term restoration of functional sight in patients 
with improvement in object recognition, mobility, 
independent living, and general quality of life. 
 
ARCHAEBACTERIAL HALORODOPSIN 
  A novel mechanism to create electric signals in the visual 
pathway that substitute for the usual input from 
photoreceptors, besides for electronic retinal implants, is the 
use of a light-activated channel. 
  In most retinal degenerations, photoreceptor degeneration 
precedes inner retinal degeneration by several years. It has 
been suggested introduction of bacterial rhodopsin through 
gene transfer can render the cells of inner retina 
photosensitive, thus substituting for the usual input from 
photoreceptors. There was a restoration of basic vision 
driven behavior in the rodent. Expression of the bacterial 
protein channelrhodopsin-2 would generate a light-gated 
cation channel within the cellular membrane that would 
allow for depolarization events upon light stimuli [80]. 
  In RP, cone photoreceptors survive longer and may be 
accessible to therapeutic manipulation. Busskamp and 
colleagues reactivated the remnant cones in two mouse 
models of RP by the introduction of a bacterial form of 
rhodopsin, halorhodopsin, through AAV mediated gene 
transfer [81]. The reactivated cones enabled RD mice to 
perform visually guided behaviors. 
RETINAL TRANSPLANT 
  Retinal transplant is another therapeutic strategy to 
restore vision in patients with advanced degenerative retinal 
disease and it is an area of increasing interest in retinal 
research. The same principle of retinal prosthesis can be 
applied to retinal transplant, but in this case new cells instead 
of electronic devices replace the degenerated photoreceptors. 
The retina is a good substrate for stem cell therapies, as it 
has the optimal combination of ease of surgical access, 
combined with the possibility to assess transplanted cells 
directly through the clear ocular media [82]. 
  Different tissues can be source of cells that can be used 
for transplantation: fetal tissue, embryonic stem cells, neural 
stem cells, somatic cells, induced pluripotent stem cells and 
RPE. 
Fetal Tissue 
  Studies using whole sheets of fetal neural retina 
transplanted into the subretinal space have shown survival 
and differentiation of the grafted tissue [83, 84]. Some 
studies have described improvements in vision although it is 
unclear whether it is just due to enhanced survival of host 
photoreceptors via trophic signals from the donor tissue [85-
87]. 
  The main limitation of this type of transplant is physical 
because when transplanting the whole neural retina there is a 
problem with space and disorganization of host neural retina. 
It would be more physiological to try to transplant only a 
sheet of immature photoreceptors [88]. 
Stem Cells 
  Stem cells that could be used for photoreceptor 
replacement are embryonic stem cells (ESC) and neural stem 
cells (NSC) isolated from the adult mammalian brain and the  
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adult ciliary margin of the mouse and human eye [89]. 
Limitations include the ethical problems when working with 
embryonic stem cells and how to direct the correct 
differentiation into specific adult cell types with their proper 
function [88]. 
Therapeutic Cloning 
  Also known as somatic cell nuclear transfer (SCNT). The 
basis of this technique is to create embryonic stem cells that 
could differentiate into photoreceptors from an adult somatic 
cell of the patient [88]. One of the advantages of SCNT is 
that the risk of immunological rejection is alleviated because 
the patient's own genetic material is used. Although research 
in this field is progressing rapidly, there are no results 
applicable to retinal dystrophies as yet. 
Induced Pluripotent Stem Cells (iPSC) 
  iPSC are a type of pluripotent stem cell artificially 
derived from a non-pluripotent cell, typically an adult 
somatic cell, by forcing the expression of specific genes. 
Depending on the methods used, reprogramming of adult 
cells to obtain iPSC may pose significant risks that could 
limit its use in humans. For example, if viruses are used to 
genomically alter the cells, the expression of oncogenes may 
potentially be triggered [90]. The method of reprogramming 
has been optimized to avoid the use of retroviruses, making 
the process considerably safer [82]. Recent development of 
human iPSC and the ability to specifically induce 
differentiation into cells with human photoreceptor 
phenotype has now provided us with the opportunity for 
embryo-free autologous transplantation and opens a new 
path in retinal transplant [91]. 
RPE Transplantation 
  The RPE constitutes with the photoreceptor layer a 
functional unit that provides the transducing interface for 
visual perception [7] and it also plays an important role in 
the maintenance of the extracellular matrix. These properties 
have encouraged many researchers to try to improve vision 
by RPE transplantation. Radtke et al. published a series of 10 
patients affected by RP and dry age-related macular 
degeneration (AMD) who received implants of neural retinal 
progenitor cell layers with RPE [92]. The study showed 
improvement in VA in 70% of patients and demonstrated the 
efficacy and safety of the RPE transplant in animal models 
of retinal degeneration. One disadvantage of this 
transplantation technique is that it will be of limited benefit 
in patients with severe loss of photoreceptors [93]. The 
hypothetical combination of RPE transplantation with other 
modalities of treatment, such as gene transfer, remains an 
exciting future prospect [94]. 
  The treatment of RP patients by photoreceptor precursor 
cell transplantation to the human retina remains a promising 
strategy for retinal repair. For retinal dystrophies caused by 
photoreceptor-specific gene mutations, autologous adult 
derived cells do not initially appear to be the best source of 
new retinal neurons, as the genetic mutation will remain. 
Future treatment for retinal degeneration due to 
photoreceptor cell loss may require a combination of gene 
and cell therapeutic strategies [39, 95]. 
CONCLUSIONS AND CHALLENGES 
  The future for treating this group of devastating inherited 
diseases has never looked brighter. Approaches to therapy 
for RP now include: gene therapy, neurotrophic growth 
factors, anti-apoptotic agents, ribozyme therapy, RNAi, 
retinal transplantation, dietary supplementation, retinal 
prostheses, and stem cell therapy [96]. 
However, there remain several hurdles: 
  The success of these treatments depends on proper 
patient selection, which may include the stage of the disease, 
the patient’s age, systemic and environmental factors and 
well set out outcome measures of improvement. 
  Successful translation of new therapies also requires 
animal models of the disease. There are different natural and 
transgenic RP animal models that have different times to 
developing photoreceptor degeneration. It may be difficult to 
decide which model is most relevant to a specific study. 
Some of the mutations between humans and animals are not 
similar. The mutation and the phenotype in the animal model 
must be viewed with some degree of caution; it cannot be 
assumed that these are truly representative of the disease that 
is occurring in the patient until the phenotypes are critically 
examined using the same criteria. 
  There is tremendous genetic heterogeneity associated 
with the RP phenotype and accurate genetic characterization 
is essential for specific gene therapies. It is not known 
whether partial reversal of the biochemical defect will 
change the course of progressive retinal degeneration. 
Although RPE65-LCA has been extensively studied, a 
predictive relation between a pair of mutant RPE65 alleles 
and resulting disease severity is currently unknown. There 
may be considerable intraretinal variation of retinal 
dysfunction, degeneration and RPE health. Better 
understanding of the contribution of specific genotypes to 
disease severity may allow such predictions in the future. 
  Human results suggest that there may even be differences 
between foveal and extra-foveal cones and this may explain 
the lack of foveal functional improvement demonstrable with 
gene therapy to date [97]. Thus treating the fovea may not 
lead to fovea-specific increases in visual acuity, but this 
rather important issue has still not been resolved. 
  The importance of the RPE has not yet been established. 
In late stages, with evidence of diffuse disease of the retinal 
pigment epithelium, the genes that are transfected into the 
photoreceptor cells may not be sustainable by the RPE. 
Some patients have changes not only in the RPE, but also in 
the choroidal circulation. 
  Another issue is the variation in clinical presentation of 
patients with RP. It will be important for clinical trials in RP 
to randomize patients along the lines of recognizable 
phenotypes, because there could be a different response to 
various therapeutic procedures among the various 
phenotypes. 
  So far gene therapy trials have involved patients with 
almost no vision. The next daunting step is to include 
patients with expanses of useful and sometimes only 
moderately abnormal vision. High expectations for 
remarkable visual recoveries may have to be replaced by the 282    Current Genomics, 2011, Vol. 12, No. 4  Sahni et al. 
less exciting but still useful outcome of slowed progression 
of these ultimately blinding disorders. 
  Effective delivery of the therapy, both genetic material 
and neurotrophic factors to the target tissue has been a 
formidable task. The blood-retinal barrier prevents most 
drugs administered topically or systemically from reaching 
an effective dose in the retina. One of the key methods 
would involve methods to introduce the molecule without 
causing a retinal detachment. This has been achieved to 
some extent with CNTF encapsulated cell technology, 
thereby achieving adequate intraocular concentration of the 
drug and limiting systemic toxicity. However, weekly, 
monthly or yearly intraocular injections represent distinct 
disadvantages to patients who require treatment during a 
lifetime. Longer follow up is needed to establish the success 
of CNTF technology, which may then be applicable for other 
treatment types. 
  Translational clinical research initiatives are finally 
offering hope to relatives and patients with RP. Genotyping 
is one of the biggest resource challenges we face. State- of-
the-art clinical facilities are needed to administer and 
evaluate novel investigational therapies. Even if the promise 
of gene replacement therapy is fully realized, the basic 
research and clinical trials that precede successful gene 
therapy take years. We suggest that research should be 
directed to identifying the patho-physiological processes 
common to all the photoreceptor degenerations and a more 
general treatment would fill an enormous therapeutic gap. 
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